Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2005 1
2007 1
2008 1
2010 1
2015 1
2016 1
2017 1
2018 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.
Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Cuestas ML, et al. Pharm Res. 2010 Jul;27(7):1184-202. doi: 10.1007/s11095-010-0112-z. Epub 2010 Mar 24. Pharm Res. 2010. PMID: 20333454 Review.
In spite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection is still the most common cause of liver cirrhosis and hepatocellular carcinoma, with more than 400 million people chronic …
In spite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) in
Applications of human hepatitis B virus preS domain in bio- and nanotechnology.
Toita R, Kawano T, Kang JH, Murata M. Toita R, et al. World J Gastroenterol. 2015 Jun 28;21(24):7400-11. doi: 10.3748/wjg.v21.i24.7400. World J Gastroenterol. 2015. PMID: 26139986 Free PMC article. Review.
Human hepatitis B virus (HBV) is a member of the family Hepadnaviridae, and causes acute and chronic infections of the liver. ...The selective delivery of diagnostic molecules to target hepatocytic cells can also improve
Human hepatitis B virus (HBV) is a member of the family Hepadnaviridae, and causes acute and chronic infectio
Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.
Rensen PC, de Vrueh RL, van Berkel TJ. Rensen PC, et al. Clin Pharmacokinet. 1996 Aug;31(2):131-55. doi: 10.2165/00003088-199631020-00005. Clin Pharmacokinet. 1996. PMID: 8853935 Review.
The hepatitis B virus (HBV) is the world's most important chronic virus infection. ...As infection and replication of HBV mainly occur in liver parenchymal cells, selective targeting of antiviral nucleoside analogues as well …
The hepatitis B virus (HBV) is the world's most important chronic virus infection. ...As infection
Delivery of toll-like receptor 3 ligand poly(I:C) to the liver by calcium phosphate nanoparticles conjugated with an F4/80 antibody exerts an anti-hepatitis B virus effect in a mouse model.
Du Y, Yang X, Li J, Sokolova V, Zou S, Han M, Yan H, Wey K, Lu M, Dittmer U, Yang D, Epple M, Wu J. Du Y, et al. Acta Biomater. 2021 Oct 1;133:297-307. doi: 10.1016/j.actbio.2021.01.045. Epub 2021 Feb 1. Acta Biomater. 2021. PMID: 33540061
Hepatitis B virus (HBV) is a global health issue, but currently available anti-HBV drugs have limited success. ...This may provide important insight into future HBV immunotherapy based on nanoparticle-mediated drug delivery....
Hepatitis B virus (HBV) is a global health issue, but currently available anti-HBV drugs have limited success. .
RNAi for treating hepatitis B viral infection.
Chen Y, Cheng G, Mahato RI. Chen Y, et al. Pharm Res. 2008 Jan;25(1):72-86. doi: 10.1007/s11095-007-9504-0. Epub 2007 Dec 12. Pharm Res. 2008. PMID: 18074201 Free PMC article. Review.
Chronic hepatitis B virus (HBV) infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC). ...There is an in-depth discussion on the (1) mechanisms of RNAi, (2) methods for siRNA/shRNA production, (3) ba …
Chronic hepatitis B virus (HBV) infection is one of the leading causes of liver cirrhosis and hepa …
Hepatitis B Gene Therapy Coming to Age.
Soriano V. Soriano V. AIDS Rev. 2018 Apr-Jun;20(2):125-127. AIDS Rev. 2018. PMID: 29938706 Review.
The major pandemics caused by chronic viral infections is produced by HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV), with estimates of 38, 70, and 250 million people worldwide, respectively (Fig. 1). ...However, they interact with a …
The major pandemics caused by chronic viral infections is produced by HIV, hepatitis C virus (HCV), and hepatitis B
Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Sato Y, Matsui H, Yamamoto N, Sato R, Munakata T, Kohara M, Harashima H. Sato Y, et al. J Control Release. 2017 Nov 28;266:216-225. doi: 10.1016/j.jconrel.2017.09.044. Epub 2017 Oct 3. J Control Release. 2017. PMID: 28986168
Lipid nanoparticles (LNPs) are the leading technology for delivering short interfering RNA (siRNA) in vivo. While numerous attempts to improve the efficiency of siRNA delivery have been reported, only a few studies of the mechanism of LNP-mediated toxicity and attem …
Lipid nanoparticles (LNPs) are the leading technology for delivering short interfering RNA (siRNA) in vivo. While numerous attempts to im
Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA.
Michler T, Große S, Mockenhaupt S, Röder N, Stückler F, Knapp B, Ko C, Heikenwalder M, Protzer U, Grimm D. Michler T, et al. EMBO Mol Med. 2016 Sep 1;8(9):1082-98. doi: 10.15252/emmm.201506172. Print 2016 Sep. EMBO Mol Med. 2016. PMID: 27473329 Free PMC article.
Hepatitis B virus (HBV) is a promising target for therapies based on RNA interference (RNAi) since it replicates via RNA transcripts that are vulnerable to RNAi silencing. ...Using recombinant Adeno-associated virus (AAV) 8 vectors for delive
Hepatitis B virus (HBV) is a promising target for therapies based on RNA interference (RNAi) since it rep
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.
Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Morrissey DV, et al. Nat Biotechnol. 2005 Aug;23(8):1002-7. doi: 10.1038/nbt1122. Epub 2005 Jul 24. Nat Biotechnol. 2005. PMID: 16041363 Free article.
The efficacy of lipid-encapsulated, chemically modified short interfering RNA (siRNA) targeted to hepatitis B virus (HBV) was examined in an in vivo mouse model of HBV replication. ...The improved efficacy of siRNA-SNALP compared to unfor …
The efficacy of lipid-encapsulated, chemically modified short interfering RNA (siRNA) targeted to hepatitis B virus
Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?
Abo-Zeid Y, Urbanowicz RA, Thomson BJ, Irving WL, Tarr AW, Garnett MC. Abo-Zeid Y, et al. Int J Pharm. 2018 Aug 25;547(1-2):572-581. doi: 10.1016/j.ijpharm.2018.06.027. Epub 2018 Jun 13. Int J Pharm. 2018. PMID: 29908332 Free article.
Human Immunodeficiency virus (HIV), Hepatitis B. Virus infections represent 44% of newly emerging infections. ...Nanoparticles (NP) can be effectively targeted to the liver, and therefore it could be used for improving th
Human Immunodeficiency virus (HIV), Hepatitis B. Virus infections represent 44% of newly emerging infections